When Jean-Pierre Garnier took over as CEO of GlaxoSmithKline seven years ago, the company's reputation on corporate social responsibility was at its nadir. As part of a coalition of 39 pharmaceutical companies, the drugmaker was suing Nelson Mandela's South African government for voiding patents on prescription drugs. Mandela's top priority was giving desperately sick patients access to HIV treatments, and GSK...was standing in the way. "It was a public relations disaster," Garnier concedes. The experience convinced Garnier that GSK should lead the crusade to improve access to medicine. In 2001, GSK became the first major drugmaker to sell its AIDS medicines at cost in 100 countries worldwide...GSK [now] sells 90% of its vaccines, in volume terms, at not-for-profit prices to customers in the developing world.